Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?

Future Med Chem. 2012 Apr;4(5):587-8. doi: 10.4155/fmc.12.8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Ligands
  • Metabolic Diseases / drug therapy
  • Peroxisome Proliferator-Activated Receptors / agonists*
  • Peroxisome Proliferator-Activated Receptors / metabolism
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors*
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Thiazolidinediones / chemistry
  • Thiazolidinediones / therapeutic use

Substances

  • Ligands
  • Peroxisome Proliferator-Activated Receptors
  • Receptors, Cytoplasmic and Nuclear
  • Thiazolidinediones
  • farnesoid X-activated receptor